Solvonis Therapeutics plc (LON:SVNS)

London flag London · Delayed Price · Currency is GBP · Price in GBX
0.2378
+0.0078 (3.39%)
May 8, 2026, 4:19 PM GMT
Market Cap15.65M +370.2%
Revenue (ttm)n/a
Net Income-5.74M
EPS-0.00
Shares Out6.81B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume32,967,323
Average Volume34,382,809
Open0.2331
Previous Close0.2300
Day's Range0.2300 - 0.2500
52-Week Range0.1250 - 0.4000
Beta1.19
RSI42.79
Earnings DateSep 11, 2026

About Solvonis Therapeutics

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product candidate includes SVN-SDN-14 for the treatment of post-traumatic stress disorder. The company was formerly known as Graft Polymer... [Read more]

Founded 2017
Employees 3
Stock Exchange London Stock Exchange
Ticker Symbol SVNS
Full Company Profile

Financial Performance

Financial Statements